Swiss National Bank reduced its stake in shares of Dynavax Technologies Corp. (NASDAQ:DVAX) by 3.8% during the second quarter, Holdings Channel reports. The fund owned 58,778 shares of the biopharmaceutical company’s stock after selling 2,300 shares during the period. Swiss National Bank owned approximately 0.15% of Dynavax Technologies Corp. worth $857,000 as of its most recent filing with the SEC.
Other hedge funds have also recently modified their holdings of the company. Meeder Asset Management Inc. purchased a new stake in shares of Dynavax Technologies Corp. during the second quarter valued at about $107,000. Legal & General Group Plc raised its stake in shares of Dynavax Technologies Corp. by 19.2% in the first quarter. Legal & General Group Plc now owns 6,235 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 1,003 shares during the last quarter. Boston Advisors LLC raised its stake in Dynavax Technologies Corp. by 1.3% in the second quarter. Boston Advisors LLC now owns 12,330 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 155 shares during the last quarter. Alpine Partners VI LLC bought a new stake in Dynavax Technologies Corp. during the first quarter worth about $192,000. Finally, Fox Run Management L.L.C. bought a new stake in Dynavax Technologies Corp. during the second quarter worth about $295,000. Hedge funds and other institutional investors own 83.82% of the company’s stock.
Shares of Dynavax Technologies Corp. (NASDAQ:DVAX) traded down 0.7846% during trading on Friday, reaching $10.6855. The company’s stock had a trading volume of 885,074 shares. The company’s market cap is $411.36 million. Dynavax Technologies Corp. has a 12-month low of $10.11 and a 12-month high of $29.86. The company has a 50 day moving average of $13.08 and a 200 day moving average of $15.75.
Dynavax Technologies Corp. (NASDAQ:DVAX) last released its quarterly earnings results on Friday, August 5th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.68) by $0.07. The firm earned $2.65 million during the quarter, compared to analysts’ expectations of $1.58 million. Dynavax Technologies Corp. had a negative return on equity of 64.43% and a negative net margin of 2,068.75%. The business’s quarterly revenue was up 70.8% on a year-over-year basis. During the same quarter last year, the business earned ($0.80) earnings per share. On average, analysts anticipate that Dynavax Technologies Corp. will post ($2.96) EPS for the current fiscal year.
A number of research firms recently issued reports on DVAX. S&P Equity Research boosted their price objective on Dynavax Technologies Corp. from $11.28 to $16.01 in a research note on Friday, September 2nd. William Blair reiterated a “buy” rating and set a $45.00 price objective on shares of Dynavax Technologies Corp. in a research note on Tuesday, September 6th. RBC Capital Markets reiterated a “sector perform” rating and set a $16.00 price objective on shares of Dynavax Technologies Corp. in a research note on Wednesday, September 7th. Zacks Investment Research upgraded Dynavax Technologies Corp. from a “sell” rating to a “hold” rating in a research note on Wednesday, June 15th. Finally, Cowen and Company reiterated an “outperform” rating and set a $45.00 price objective on shares of Dynavax Technologies Corp. in a research note on Tuesday, September 6th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Dynavax Technologies Corp. currently has an average rating of “Hold” and a consensus target price of $25.86.
About Dynavax Technologies Corp.
Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).
Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Corp. (NASDAQ:DVAX).
Receive News & Ratings for Dynavax Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corp. and related companies with MarketBeat.com's FREE daily email newsletter.